StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.67−1.15 (-9.73%)

Close on Nov 17, 2026Market cap $8.51BP/E –Yield –

Summit Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Summit Therapeutics's EV/EBITDA was 25.0× on Jan 31, 2022, against 15.7× a year earlier.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2022Jan 31, 202225.0×−8.9
2021Dec 31, 202133.8×+25.4
2020Dec 31, 20208.5×–

More Summit Therapeutics figures

See a number that looks wrong?